| Project/Area Number |
20590323
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pathological medical chemistry
|
|---|
| Research Institution | National Cancer Center Research Institute and Research Center for Innovative Oncology, National Cancer Center Hospital East |
|---|
Principal Investigator |
YAMASHITA Satoshi National Cancer Center Research Institute and Research Center for Innovative Oncology, National Cancer Center Hospital East, 研究所, ユニット長 (80321876)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2008: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | 分子腫瘍学 / がん / DNAメチル化 / メチル基転移酵素 / トランスジェニックマウス / 個体レベル / トランスジェニックラット |
|---|
| Research Abstract |
Aberrant DNA methylation is essential in carcinogenesis, and analysis using animal model is important. The aim of this study was to establish a transgenic rat that can control expression of DNA methyltransferase, Dnmt3b, and to clarify whether high Dnmt3b expression induce tumors with malignant phenotypes or not. The transgenes that can induce rat Dnmt3b2 expression were constructed. For universal use, I decided to construct transgenic mouse, and the rat cDNA was replaced by a mouse cDNA. If a transgenic mouse is established, it will enable us to assess factors that induce or suppress aberrant DNA methylation.
|
